Pasadena Fertility Clinic Expands Genetic Testing Through Global Partnership

The Southern California Reproductive Center (SCRC), which operates a clinic in Pasadena, has joined the Nucleus IVF+ Network, bringing advanced genetic testing to local patients amid rising demand for fertility services. 

Co-founded by Mark Surrey and Hal C. Danzer, SCRC will integrate Nucleus’ genetic optimization technology into preconception testing and embryo selection. This partnership allows patients to gain deeper insight into their embryos’ DNA, aiming to reduce inherited health risks and improve pregnancy outcomes. 

The move comes as Nucleus expands rapidly worldwide, now working with more than 160 clinics in India, the Middle East, and nearly all U.S. states. By joining the IVF+ Network, SCRC will offer Nucleus’ expanded carrier screening (Preview) and advanced embryo analysis (Embryo) to patients across its four California locations — Beverly Hills, Santa Barbara, Ventura, and Pasadena. 

“Patients want more insights on their embryos during IVF,” said Kian Sadeghi, founder and CEO of Nucleus Genomics. “Every patient has a loved one who suffered from a preventable condition, whether cancer, diabetes, or heart disease. SCRC, with their decades-long experience, is bringing preventive medicine to the start of life, helping patients understand their embryo’s DNA to reduce genetic risk in the next generation.” 

Surrey spotlighted the reassurance genetic screening can provide: “Our ability to provide genetic screening for our patients’ embryos gives patients access to testing that can offer reassurance,” said Mark Surrey, co-founder of Southern California Reproductive Center. “This remarkable breakthrough addresses concerns about birth defects, provides genetic analysis, and helps us assess an embryo’s potential to result in a healthy pregnancy.” 

With Nucleus, patients can opt into testing for more than 2,000 rare inherited conditions, as well as common diseases such as heart disease and diabetes. Screening also covers hereditary cancer syndromes, including hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome.

Surveys cited by Nucleus show that nearly three-quarters of U.S. adults support advanced genetic testing during IVF, according to studies published in JAMA Netw Open and Reproductive Medicine. The company already has a waitlist of more than 3,000 patients and continues to expand its IVF+ Network across the U.S. and internationally. 

For residents in Pasadena, the partnership means expanded access to cutting-edge fertility care close to home, reinforcing SCRC’s role as a trusted destination for families seeking innovative reproductive medicine.